HERITAGE
2013
Omega Pharma acquires Arterin
2013
Omega Pharma buys Etixx
2012
Omega Pharma acquires OTC-brands of GSK Europe
2012
Delisting of Omega Pharma from NYSE/Euronext
2010
Acquisition of Laboratoire de la Mer, a world leader in natural Cough & Cold products
2009
Formation of the 50/50 joint venture with Modi-Mundipharma Group in India
2009
Sale of 24% stake in Arseus
2008
Various smaller acquisitions, including Aurora (Australia, New Zealand, Singapore), Interdelta (Switzerland), Altermed (Czech Republic and Slovakia), O+A Pharma (Hungary), Hipocrate (Romania), Fishem (Turkey), and Cinetic Laboratories (Argentina)
2007
Arseus carve-out via separate IPO
2007
Inclusion of Silence in the brand portfolio through the acquisition of Persee Médica
2006
Expansion into CEE and CIS through the acquisition of Bittner Pharma
2004
Acquisition of Wartner Europe
2004
Acquisition of 60 OTC brands from Pfizer which both expanded existing activities and provided access to new European countries such as Italy, Ireland, Scandinavia and Switzerland
2004
Expansion into Italy and Scandinavia via acquisitions
2003
Expansion into Greece
2002
Introduction in the Bel 20 index and expansion into Portugal
2000
Expansion into France through the acquisition of Pharmygiène
2000
Acquisition of Chefaro (AkzoNobel OTC) with operations in UK, Spain, Germany and The Netherlands
2000
Start of the internationalization process
1998
Start of the acquisition process on the Belgian home market
1998
IPO on Euronext Brussels
1994
Management buy-out by Marc Coucke
1987
Omega Pharma is created by two pharmacists, including Marc Coucke, the current CEO. With the slogan 'By pharmacists, for pharmacists' the founders of the Company began to build a Consumer Health organization in which the relationship with pharmacists plays a central role